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A B S T R A C T
Purpose: To investigate the efﬁcacy and safety of levetiracetam in adults with intellectual disabilities who
have uncontrolled partial or generalised epilepsy.
Methods: An open label prospective study compared seizure frequency, adverse effects, participant
challenging behaviour, carers’ concerns about epilepsy and perceived participant quality of life between a
baseline observation prior to the use of levetiracetam and follow-up observations at 3, 6, 9 and 12months
afterwards. Challenging behaviour, carers’ concerns about epilepsy and perceived quality of life were
assessed using standardized measures.
Results: Recruitment was low (n = 42). Six participants did not enter the trial. Two participants withdrew
at initiation of treatment, onewith seizuresworsening and onewith a rash, and a further one later onwith
a rash; all were felt to be drug related. Three other participants withdrew for independent reasons.
Twelve months follow-up was achieved for 26 participants (62%) and at least 6 months follow-up for 30
participants (71%). Median seizure frequency reduced from baseline levels of 4.2 per week to average
post-intervention levels of 2.2 for the 30 participants (z = 2.53, p < .05). No overall change in challenging
behaviour was found, although increases in behaviour problems were reported for a minority. Patient
concerns about seizures and medical treatment declined and perceived quality of life relating to seizure
severity improved whilst that related to behaviour deteriorated. Increased adverse effects were reported
immediately after initiation of levetiracetam but declined towards baseline levels by study completion.
Discussion: Conclusions must remain tentative due to methodological weaknesses. Further investigation
of the possible changes found here within a controlled study is merited.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Establishing effective anti-epileptic therapy is particularly
important for people with intellectual disabilities. People with an
intellectual disability have an increased prevalence of epilepsy
compared to the general population with rates reported in the
literature ranging from 14% to 44%.1 Prevalence increases with
severity of intellectual disability1 and, in addition to the increased
prevalence of epilepsy, there is an increased prevalence of refractory
epilepsy requiring polytherapy/add-on therapy. Epilepsy in this
population is associated with increased morbidity and mortality,2
partly because it is associated with other co-morbidities and
increased risk of death from respiratory causes.3 The mortality risk
for the populationwith epilepsy and intellectual disability has been
shown to be ﬁve times that of the general populationwhilst the risk
ratio for peoplewith intellectual disabilitieswithout epilepsy is only* Corresponding author. Tel.: +44 29 20687213.
E-mail address: mp_kerr@yahoo.com (M. Kerr).
1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.11.0011.6.4 Presence of intellectual disability increases the likelihood of
sudden unexplained death among peoplewith epilepsy,5 due partly
to the poorer control of epilepsy and an increased susceptibility to
post-ictal apnoea and positional asphyxia.6
Alongside the awareness of the special nature of epilepsy in
people with an intellectual disability, it is recognised that the
evaluation of treatment outcome needs a distinctive focus.7,8
Seizure reduction remains a primary endpoint but other variables
are important. These include the impact of epilepsy and its
treatment on quality of life and on potentially related issues such
as patterns of behaviour. Evidence based guidelines have been
produced for the management of epilepsy among people with
intellectual disabilities.9 However, these recognise the paucity of
evidence speciﬁc to this population. Gaining an appropriately
speciﬁc evidence base for treatment intervention is an ethical
requirement, a concern which has been articulated more generally
in relation to this population.10
The purpose was to investigate the novel anti-epileptic drug,
levetiracetam. Clinical trials show the drug has anticonvulsant
effects and a good safety proﬁle. However, there is a paucity of datavier Ltd. All rights reserved.
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disabilities. The aim of this open label prospective study was to
assess the impact of levetiracetam as an add-on therapy on seizure
frequency, adverse effects, participant challenging behaviour,
carers’ concerns about epilepsy and perceived participant quality
of life. The study was conducted at a relatively early stage
following levetiracetam’s licence in order to provide evidence for
clinicians, which would allow them to advise carers and
individuals of the potential outcome of its use.
In brief, the aim was to conduct a prospective, multi-centre,
open label study to investigate the efﬁcacy and tolerability of
levetiracetam as an add-on therapy for adults with intellectual
disabilities who have uncontrolled partial or generalised epilepsy.
Efﬁcacy was assessed in terms of seizure frequency, carers’
concerns about epilepsy and perceived participant quality of life.
Participant challenging behaviour was assessed as a potentially
related outcome and also as a speciﬁc aspect of safety. Adverse
effects were monitored. Adults with intellectual disabilities who
had partial or primary generalised seizures refractory to current
treatment were recruited from clinics in the United Kingdom.
Prospective baseline observations prior to the introduction of
levetiracetam (T1) were compared to follow-up observations at 3,
6, 9 and 12 months afterwards (T2–T5).
2. Methods
2.1. Participants
The intention was to recruit at least 100 participants from 15
centres in the United Kingdom. Criteria for inclusionwere (a) being
18 years of age or over, (b) having an intellectual disability
identiﬁed by the investigator, and (c) having partial or primary
generalised seizures with aminimumof 2 seizures/month over the
8 weeks baseline period (seizure clusters not excluded). Exclusion
criteria were: (a) being aged under 18 years, (b) not having a
diagnosis of intellectual disabilities, (c) a known contra-indication
to levetiracetam, (d) use of levetiracetam in the previous 2 years,
and (e) being female with a high probability of becoming pregnant.
Participants were able to withdraw from the study at any time.
In the event, only 42 participants were recruited from 5 centres.
Under-recruitment was due to failure to gain the necessary
collaboration from other centres, which had expressed an interest
to participate, to follow the study protocol and collect the
necessary measures. Six of the 42 participants recruited did not
start medication and, therefore, were not part of the trial.
Characteristics of the 36 people exposed to the medication are
given in Table 1. A further 6 were excluded for the following
reasons: 3 withdrew early in the study for reasons unconnected to
the medication such as ill health or bereavement in the family, 2
withdrew prior to T3 due to adverse reactions to the medication
and 1 participated throughout but had no baseline data collected.
Thirty participants received the medication change and had
baseline and at least 6 months follow-up data collected (i.e., up
to and including T3). Data collection beyond this was partial for 4
participants, one of whom withdrew due to a rash believed to beTable 1
Characteristics of the participants exposed to medication (n = 36) and those (n = 30) w
Median age in
years (range)
%Male %Fami
home
Exposed to medication (n = 36) 39 (19–65) 58 53
6–12 months follow-up (n = 30) 41 (19–65) 57 47
a ABS, Adaptive Behaviour Scale.11
b ABC, Aberrant Behaviour Checklist.12associated with the medication. Characteristics of the 30
participants with 6–12 months follow-up are also set out in
Table 2.
2.2. Intervention
Participants received levetiracetam as an add-on therapy.
Speed of initiation and dosage were determined by the physician.
Dosages of levetiracetam and the number of other anti-epileptic
drugs (AEDs) taken by participants throughout the study are given
in Table 2.
2.3. Procedure and measurement
Multi-centre research ethics approval was gained in 2002
(MREC/02/7/67). Local ethical approval was gained for each
participating centre together with Trust R&D approval. Informed
consent was gained from the patient or, if this was not possible,
assent was obtained from family or carer.
Data were collected at baseline (T1), 2 months prior to the
introduction of the medication change detailed above, and for four
three-monthly follow-up points (T2–T5). Information on the
following participant characteristics was obtained at T1 from a
carer who knew the participant well: age, gender, medical history,
diagnosis, seizure types, anti-epileptic drug (AED) therapy, other
concomitant therapy, adaptive behaviour and challenging beha-
viour. The main outcome measure was the frequency of seizures.
This was assessed over a prospective 2months baseline period (T1)
and for four post-intervention 3-month periods (T2–T5). Change in
challenging behaviour was also assessed as a potential outcome, at
T1 and at each of T2–T5. At the same times, data were collected on
anti-epileptic medication, concomitant therapy, carer’s concerns
about epilepsy and their perceptions of participant quality of life.
Information on age and gender, diagnosis, seizure types, AED
therapy and other concomitant therapy was gained by the clinical
team. Participant adaptive behaviour was assessed by using Part
One of the Adaptive Behaviour Scale (2nd edition) (ABS),11 which
comprises 66 items spanning 10 domains of functioning. Internal
consistency coefﬁcients averaged across age groups for the 10
domains range from .81 to .99 and correlation coefﬁcients for test–
retest reliability from .88 to .99.11 Higher scores indicate greater
independence. Adequate levels of item discrimination, criterion-
related validity and construct validity are also reported.11 A total
ABS raw score was calculated by combining the domain scores.
Domain scores were converted to percentile rank scores and these
were averaged to gain a percentile rank equivalent of the total raw
score.
Participant challenging behaviour was assessed by using the
Aberrant Behavior Checklist (ABC).12 The ABC comprises 58
behaviours, each relating to one of ﬁve subscales: irritability,
hyperactivity, lethargy, stereotypy and inappropriate speech. High
scores indicate more or more severe challenging behaviour. The
authors report internal consistency coefﬁcients for the ﬁve
subscales ranging from .86 to .94, correlation coefﬁcients for testith 6–12 months follow-up data.
ly Median ABSa
score (range)
Median ABSa percentile
rank (range)
Median ABCb
score (range)
103 (27–301) 24 (5–86) 15 (1–87)
104 (27–301) 25 (5–86) 18 (2–87)
Table 2
Dosage of levetiracetam and number of other anti-epileptic drugs (AEDs) taken by participants (n = 30) with 6–12 months follow-up.
Starting dose T2 T3 T4 T5
Mean levetiracetam dosage (mg) (range) 275 (125–500) 908 (0–2000)a 1095 (0–2000)a 1196 (500–3000) 1107 (0–3500)b
Mean number of other AEDs (range) 1.87 (1–3) 1.83 (1–3) 1.79 (1–3) 1.82 (1–3) 1.79 (1–3)
a The zero reﬂects participants ceasing to take the drug who were followed up for the ﬁrst 6 months.
b The zero reﬂects participants who ceased to take the drug at the last data point.
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inter-rater reliability from .55 to .69.
Frequency of seizureswasmeasured by carers keeping a seizure
diary. This comprised a series of formatted sheets, each covering a
period of 1 week. Informants recorded the number of seizures
across pre-speciﬁed seizure types each day, along with any
comments (e.g., contextual information) and perceived adverse
effects of medication (e.g., symptoms and their severity). Diaries
were designed individually with personalised descriptions of
seizure types to guide recording. Overall, nine seizure types were
monitored: complex partial, secondary generalized tonic clonic,
generalized tonic clonic, atonic, myoclonic, tonic, absences, simple
partial and unclassiﬁed. Diaries were kept for a prospective 2-
month baseline period prior to intervention (T1) and for 4, 3-month
periods subsequently (T2–T5).
Carer concerns about epilepsy were obtained by using the
Glasgow Epilepsy Outcome Scale (GEOS).13 This is a scale with 35
items each rated on a scale of 0–4, with 0, never a concern/not
applicable; 1, occasionally a concern; 2, fairly often a concern; 3,
often a concern; 4, very often a concern. The 35 items divide into
four subscales: Concerns about seizures (10 items), concerns about
medical treatment (9 items), concerns about caring for a person
with epilepsy (8 items) and concerns about the social impact of
epilepsy (8 items). Subscales have strong internal consistency
(0.89  a  0.91).
Carer perceptions of participant quality of life were obtained
using the Epilepsy and Learning Disabilities Quality of Life
Questionnaire (ELDQOL).14 The ﬁnal version of ELDQOL includes
70 items covering seizure severity, seizure related injuries, anti-
epileptic drug side effects, behaviour, mood, physical functioning,
cognitive functioning, social functioning, parental concerns,
communication, overall quality of life and overall health. Items
in the behaviour (n = 9), seizure severity (n = 14), mood (n = 16)
and side effect (n = 19) domains are summed to create four
subscales. Remaining domains consist of single or several non-
summed items. The four subscales were shown to have good
internal consistency (a = .74–.95) and test–retest reliability (.80–
.92). An earlier, slightly different version than the one to be
published was used in this study. It produces the four subscales
described above. Other individual items relate to perceived seizure
control, health, quality of life and parental concerns. It is important
to note that the behaviour subscale is not synonymous with
challenging behaviour but relates more to positive social interac-
tions and activities of daily living such as bowel habit or sleep.
2.4. Analysis
Frequencies of seizures were calculated per week based on the
actual intervals between data collection points. Frequencies of
occurrence across different seizure types were summed at each
time point to obtain a total seizure frequency. Analysis was also
performed on the total minus absence andmyoclonic seizures as it
was felt that, such were the problems in recording these seizures,
their presence may affect the results. For both of these summary
variables and for each seizure type separately, the mean post-
intervention seizure frequency was calculated. This was done bysumming T2–T5 measures and dividing by 4 for the 26 participants
with complete 12 months follow-up datasets, and by summing T2
and T3 measures and dividing by 2 for the additional 4 participants
with only 6 months follow-up data. Other outcomes (ABC, GEOS
and ELDQOL) were treated similarly. Changes from baseline to the
mean post-intervention were investigated, as also were changes to
the last post-intervention data point. In addition, those partici-
pants who hadmean post-intervention seizure frequencies at least
50% below baseline levels were identiﬁed.
The analysis approach described above was adopted because no
follow-up data were obtained for those participants who withdrew
from the study for reasons either related or unrelated to the
medication change. An intention-to-treat analysis would conven-
tionallybebasedonall 36participantswhoentered the trial. Suchan
analysis could only be undertakenhere by replacingmissing data. In
order to explore the potential bias due to only analysing change in
seizure frequency for those who reached at least the half-way point
of the trial, an intention-to-treat analysis was conducted by (a)
carrying forward the baseline seizure frequency data for the 4
participants who withdrew before T2, (b) carrying forward the T2
seizure frequencydata for theparticipantwhowithdrewbetweenT2
and T3 and (c) using the T2 data for the T1 point for the participant for
whom no baseline data were collected. An additional analysis was
also undertaken based on 33 participants, excluding only the 3who
withdrew for reasons unrelated to the medication. In both cases, all
changes in seizure frequency explored reached statistical signiﬁ-
cance. This was not the case for the analysis approach adopted, as is
made clear below. The increase in sample size in moving to the
intention-to-treat analysis outweighed the addition of caseswithno
pre-post change in the calculation of statistical signiﬁcance. The
analytic approach presented is the more conservative.
The normality of the data for each outcome variable at each data
collection point was tested using a series of Kolmogorov–Smirnov
tests. The great majority were highly signiﬁcant, indicating
substantial departure from normality. Non-parametric tests of
difference (Wilcoxon signed ranks test) or correlation (Spearman’s
rank correlation coefﬁcient) were, therefore, used throughout. The
median is given in the results section as the most meaningful
indicator of central tendency.
3. Results
3.1. Seizure frequency
Changes in seizure frequencies from baseline are given in
Table 3. All ﬁgures referring to seizure frequency are the average
number of occurrences per week. Total seizure frequency
signiﬁcantly reduced (z = 2.53, p < .05 to post-baseline mean,
z = 3.75, p < .001 to last data point). Degree of changewas similar
with absences and myoclonic seizures removed. There were 13
participants whose mean post-intervention seizure frequency was
50% of the baseline level or less. They changed from a baseline
median frequency of 7.8 to a mean post-intervention median
frequency of 1.5. Two participants became seizure free after the
introduction of levetiracetam. One participant had a substantially
increased seizure frequency by the end of the study (18.5)
Table 3
Median seizure frequencies at baseline,mean post-intervention and at the last post-
intervention data point, and signiﬁcance of change.
Seizure type Baseline Post-intervention
Mean Last point
All (n = 30) 4.2 2.2 2.1
All—absences and myoclonic (n = 30) 3.5 1.5 1.4
Complex partial (n = 14) 3.3 1.0 1.0
Secondary generalized tonic clonic (n = 5) 1.3 0.8 0.5
Generalized tonic clonic (n = 18) 0.6 0.3 0.1
Atonic (n = 5) 0.2 0.5 0.2
Myoclonic (n = 5) 1.0 2.6 1.1
Primary generalized tonic (n = 5) 2.3 4.3 2.2
Absences (n = 8) 1.7 0.6 0.5
Simple partial (n = 3) 10.0 4.3 0.4
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of less than one seizure per week. Reduction in complex partial
seizures (n = 14) and secondary generalized tonic clonic seizures
(n = 5) was greater than in generalized tonic clonic seizures
(n = 18), atonic seizures (n = 5), myoclonic seizures (n = 5), primary
generalized tonic seizures (n = 5), absence seizures (n = 8) or
simple partial seizures (n = 3).
3.2. Challenging behaviour, concerns about epilepsy and perceived
quality of life
Total ABC scores did not change (see Table 4). There was also no
change on any of the ﬁve subscales. Neither was there an
association between the total frequency of seizures and total
ABC score at any time point nor the change in the total frequency of
seizures and change in total ABC score between baseline and the
average post-intervention.
A number of GEOS questionnaires at each time point had one or
two items which were not completed. Which participants were
affected varied across time points so that the potential impact of
missing data on the calculation of subscale and total scores was
considerable. A decision was, therefore, taken to replace missing
data by the average for the item and restrict comparison to the 26
participants for whom 12 months follow-up was achieved. Total
scores on the GEOS signiﬁcantly declined, as did two subscale
scores: concerns about seizures and concerns about medical
treatment (see Table 4). The two remaining subscales, concerns
about caring for a person with epilepsy and concerns about the
social impact of epilepsy, did not change.
Missing data on the ELDQOL meant that analyses were
restricted to 27 participants (see Table 4). Scores on the behaviour
subscale deteriorated and the seizure severity subscale improved.
Otherwise, there were no other signiﬁcant subscale changes. In
relation to individual items, the only item to change signiﬁcantlyTable 4
Median baseline and mean post-intervention scores on the GEOS and ELDQOL, and sig
Scale Baselin
ABC (n = 30) Total score 18.0
GEOS (n = 26) Total score 45.2
Concerns about seizures 14.3
Concerns about treatment 13.5
Concerns about caring 7.5
Concerns about social impact 7.0
ELDQOL (n = 27) Behaviour 15.0
Seizure severity 28.0
Mood 24.0
Side effects 33.0was a lessening of parental concerns (baseline median = 3.0,
average post-intervention median = 2.0, z = 2.40, p < .05).
3.3. Adverse effects
As reported above, there were 42 participants recruited. Six did
not start medication; 36 people were exposed to the medication.
Five people withdrew after baseline but before either the T2 or T3
data collection round. Therewere no safety issues for three of these
participants; reasons for withdrawal were unconnected to the
medication. The other two experienced early adverse effects
believed to be related to levetiracetam, which comprised
deterioration in seizure control and a rash. Table 5 sets out
adverse effects reported for the remaining 31 participants who
were followed up for at least two post-intervention data points
(including the person who was excluded from the analysis to this
point as no baseline data were collected). One of these 31
participants withdrew from the trial after T3 because of a rash
attributed to the medication. No adverse effects were reported for
11 of the 31 participants (35%) at any time during the study.
Adverse effects were reported for 5 participants at T1 (17%).
Adverse effects continued to be reported for these 5 participants at
subsequent data points, that is, after the addition of levetiracetam.
For 2 of these 5 people, subsequent adverse effects were broadly
similar to those at baseline, for 2 they appeared to change, and for
one there was a mixture of continuation and change. Adverse
effects began to be reported for 15 participants from T2 onwards
(48%). As can be seen from Table 5, there was an increase at T2 in
reporting of fatigue, behaviour problems, digestion problems and a
variety of physical problems. The number of participants reporting
adverse effects was greatest at T2 (18), thereafter declining.
Adverse effects continued to be reported by 7 participants at T5, the
5 participants at T1 and 2 others.
No adverse effects were reported for 67% of participants with
higher levels of challenging behaviour at the outset of the study
(i.e., those with ABC scores above the median). However, the two
participants for whom challenging behaviour was reported as an
adverse effect at the last data point were amongst this subgroup.
Such behaviour had been ﬁrst reported for one participant at T2
(i.e., after introduction of levetiracetam). Otherwise, levetiracetam
appeared to be well tolerated by this subgroup.
4. Discussion
This studywas an open label uncontrolled trial and, as such, one
can only reach tentative conclusions relating to treatment effects.
In addition, there is sparse information about other treatment
changes, which may have co-occurred with the change of
medication under investigation. Therefore, a more deﬁnitive
conclusion must await a more rigorous trial. Such a trial appearsniﬁcance of change.
e Mean post-intervention Signiﬁcance of change
18.7 NS
31.2 z = 2.12, p < .05
9.1 z = 2.02; p < .05
7.9 z = 2.63, p < .01
7.2 NS
5.9 NS
16.5 z = 2.03, p < .05
23.3 z = 2.10, p < .05
24.7 NS
29.7 NS
Table 5
Reported adverse effects of pre-existing anti-epileptic drugs (AEDs) (T1) and pre-
existing AEDs together with levetiracetam (T2–T5).
Side effect Number of participants reporting side effect (n = 31)
T1 T2 T3 T4 T5 Total
a
Inactivity
Tired/lethargic 2 10 5 3 3 12
Quiet 1 1 1 1 1
Confused 1 1
Tired/lethargic 2 10 5 3 3 12
Total inactivitya 2 10 5 4 3 12
Behaviour
Uncooperative 1 2 2 1 3
Challenging behaviour 3 1 3 2 6
Bad tempered 1 1 1
Demanding 1 1 1
Shouts in sleep 1 1
Total behavioura 2 5 4 3 2 8
Mood
Agitated 1 2 2 1 1 5
Elated 1 1 1 1
Jumpy 1 1
Tearful 1 1 1 1 1
Moody/low mood 2 1 1 1 2
Unsettled 1 1 1
Anxious 1 1
Total mooda 2 5 4 3 3 8
Digestion
Loss of appetite 1 1 1 1
Constipation 1 1
Upset stomach 1 1
Nausea 1 1 1
Total digestiona 4 2 1 4
Physical
Unsteady 1 1 1 1 1 1
Headache 2 2
Dizzy 1 1
Blisters 1 1
Shakes 1 1 1 1 2
Feeling warm 1 1 1 1 1
Twitching 1 1 1
Gasping for air 1 1
Hand shaking/spasms 1 1 2
Total physicala 2 6 3 4 3 10
Other
Loss of seizure warning 1 1
Overall totala 5 18 11 11 7 20
a The total column and rows set out the total number of participants reported
adverse effects.
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current medication was found to be associated with a reduction in
total seizure frequency, limited alteration in challenging behaviour
and improvement in carer concerns about the effects of seizures
and medical treatment. In addition, some aspects of perceived
quality of life appeared to improve. Adverse reactions were
experienced early. These either led to immediate drug disconti-
nuation or reduced with time.
Before expanding on these ﬁndings, it is important to discuss a
number of other weaknesses which affect interpretation. Multiple
testing gives rise to a danger of Type 1 error, namely the acceptance
of a difference as real when it may reﬂect chance variation. Inrelation to reduction in seizure frequency, we have restricted
ourselves to testing the overall change in total seizure frequency.
We have also tested for change in ﬁve areas of the GEOS and four
areas of the ELDQOL. It is possible that there is some risk of Type 1
error in these analyses. There was a reduction in overall seizure
frequency which was accompanied by lowered carer concern
about seizures and medical treatment and improved quality of life
on the seizure severity subscale. There was no great evidence of
randomly occurring signiﬁcant differences found outside this
cluster of ﬁndings; more general concerns and quality of life issues
remained unaltered.
The under-recruitment in the sample gives rise to a greater
likelihood of making Type 2 error, that is concluding that a real
difference is only due to chance. Changes would be more clearly
demonstrated in a study with a larger sample of the size originally
planned.
The sample was not drawn at random and its representative-
ness is not known. In addition, there was no control group and
hence no control for maturation, history or regression to the mean,
should presentation at clinic for drug review have been pre-
cipitated by a period of increased occurrence of seizures. Therefore,
caution must be exercised in attributing the changes observed to
the change in medication. However, in relation to maturation,
participants were drawn from a population who have character-
istically experienced seizures refractory to treatment for a long
time. That seizure frequency should reduce spontaneously is
somewhat unlikely. In relation to history, it is a weakness that
information on concomitant therapy is imprecise. However, the
information which was collected and presented in Table 2
indicates that the prescription of other AEDs remained at a
consistent level throughout the study. Regression to themean from
an atypically high seizure frequency which may have prompted
presentation for drug review is another concern. Here, the study at
least has the merit of a prospective baseline seizure frequency
measured over a period of 2 months before medication change.
4.1. Seizure control
Numerous studies have shown the anticonvulsant properties of
levetiracetam, so it is not particularly novel for this study to have
shown improved seizure control associated with the introduction
of this medication. However, studies of people with an intellectual
disability are less common and, when reported, tend to summarise
seizure control generally in terms of ‘‘responders’’ and ‘‘non-
responders’’ rather than to quantify change in seizure frequency as
done here. Seizure change was found for complex partial and
secondary generalized tonic clonic seizures. The numbers are small
and analysis should be cautious. However, the absence of
signiﬁcant change in more generalised epilepsies is consistent
with the refractory nature of epilepsy among people with
intellectual disability. Seizure deterioration was limited unlike
other studies.15
4.2. Challenging behaviour
Family or carer concerns about behaviour change as a result of
epilepsy treatment are commonly encountered in clinical practice.
We believe our study to be the ﬁrst on levetiracetam which has
used a well-validated population appropriate measure of beha-
viour disorder. Unlike the ﬁndings of Hurtado et al.,16 this study
showed no signiﬁcant general alteration in challenging behaviour.
The lack of consistency between the two studies may be due to
differences in deﬁnition of challenging behaviour and how
challenging behaviour was measured. However, ABC scores did
rise for some individuals. There were 8 participants for whom
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scores increased aftermedication for 4, went down for 2 and stayed
at broadly the same low level for the other 2. Care needs to be taken
about impact on challenging behaviour among a minority of
recipients.
4.3. Concerns about epilepsy and perceived quality of life
The signiﬁcant lessening of carer concern relating to seizures
and treatment would appear to reﬂect the impact on seizure
control. The other two subscales, concerns about caring for a
person with epilepsy and concerns about the social impact of
epilepsy, have items which are more general in nature. It is
probably unrealistic that short-term reduction in seizure fre-
quency not leading to seizure freedom would be able to inﬂuence
these variables. However, it is possible that longer term experience
of reduced seizure frequency could lead to reduced concern. A
similar distinction would appear reasonable in relation to the
signiﬁcant improvement in perceived quality of life relating to
seizure severity compared to the absence of change in more
general social or developmental issues. Understanding the
negative effect on perceived adaptive functioning apparent in
the change in the ELDQOL behaviour subscale is more complicated.
The subscale reﬂects parental/carer perceptions over such issues as
alertness, awareness, concentration, expression of wants and
understanding, as well as physical functioning in terms of sleep
quality and bladder/bowel control. Deterioration may reﬂect the
increase in reported adverse effects concerning fatigue, sleepiness,
digestion problems and a variety of physical problems. However,
although these reported adverse effects reduced with time, the
deterioration in the behaviour subscale did not reverse.
4.4. Adverse effects
The ability to explore treatment emergent adverse effects was a
major aim. In order to achieve this, retention, challenging
behaviour, perceived adverse effects and diary recorded adverse
affects were addressed. At T5, 27 out of the 36 participants exposed
to the drug (75%) remained on medication (the 26 participants
with full 12-month follow-up and the one who was excluded due
to absence of baseline data); 3 (8%) withdrew for what were
believed to be drug related adverse effects. No general change was
found in challenging behaviour as assessed by the ABC or in
perceived adverse effects, as reﬂected in the ELDQOL side effects
subscale. Diary recorded adverse effects showed a pattern of
increased concerns immediately following the addition of the drug
reducing over time to a level only slightly above baseline. Reported
increases in behaviour problems matched by increased post-
intervention ABC scores were found for a minority (13%).
5. Conclusions
This study has shown that levetiracetam could be a useful add-
on therapy for epilepsy among peoplewith intellectual disabilities.
On the basis of these ﬁndings, its use is likely to lead to some
seizure reduction with only limited impact on challenging
behaviour. Serious adverse effects are uncommon, tend to
attenuate with time or can be managed by drug withdrawal.
Clinicians should observe for these, expect some early treatment
effects and be prepared to support carers and individuals in
responding to concerns raised during treatment.Conﬂicts of interest
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